Welcome to our dedicated page for Sarepta Therapeutics SEC filings (Ticker: SRPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sarepta Therapeutics, Inc.'s SEC filings document an operating biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under SRPT. Form 8-K reports furnish quarterly and annual financial results, product revenue disclosures for ELEVIDYS and PMO therapies, and clinical or regulatory updates for Duchenne muscular dystrophy treatments and siRNA pipeline programs.
Other filings cover proxy governance, executive compensation, equity-award plans and leadership-transition disclosures. Material-event reports also describe capital-structure actions, including exchange agreements for convertible senior notes, issuance of new convertible notes, common stock consideration and related indenture terms.
Boor Kathryn Jean reported acquisition or exercise transactions in this Form 4 filing.
Sarepta Therapeutics, Inc. director Kathryn Jean Boor received an equity grant in the form of restricted stock units. She was granted 16,875 RSUs, each representing one share of common stock, at no cash cost. The RSUs vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders that is at least 50 weeks after the prior year's meeting. Following this grant, she directly holds 25,138 shares of common stock.
Mayo Stephen reported acquisition or exercise transactions in this Form 4 filing.
Sarepta Therapeutics director Stephen Mayo received an equity grant in the form of restricted stock units. He was awarded 16,875 RSUs of common stock at no purchase price. Each RSU represents one share of common stock.
The RSUs will vest on the earlier of the one-year anniversary of the grant date and the next annual meeting of stockholders that occurs at least 50 weeks after the prior year’s annual meeting. Following this award, Mayo directly holds 18,640 shares of Sarepta common stock.
Wigzell Hans Lennart Rudolf reported acquisition or exercise transactions in this Form 4 filing.
Sarepta Therapeutics director Hans Lennart Rudolf Wigzell reported a stock-based compensation grant. He was awarded 16,875 restricted stock units (RSUs), each representing one share of Sarepta common stock at no cash cost. The RSUs will vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders that occurs at least 50 weeks after the prior year’s annual meeting. Following this award, Wigzell directly holds 42,098 shares of Sarepta common stock. This represents a routine equity compensation grant rather than an open-market share purchase.
BEHRENS M KATHLEEN reported acquisition or exercise transactions in this Form 4 filing.
Sarepta Therapeutics director Kathleen M. Behrens reported a compensation-related equity grant rather than an open-market trade. She was awarded 16,875 restricted stock units (RSUs), each representing the right to receive one share of common stock at no cost. According to the terms, these RSUs will vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders that occurs at least 50 weeks after the prior year’s annual meeting. Following this grant, she holds 214,357 shares of common stock directly, and a separate filing entry shows 10,000 shares of common stock held indirectly by a trust as a reported holding.
Sarepta Therapeutics, Inc. reported that director Deirdre P. Connelly acquired 16,875 shares of common stock through a grant of restricted stock units (RSUs) at $0.00 per share as director compensation. Following this award, she directly holds 22,100 shares of Sarepta common stock.
The footnote explains that each RSU represents one share of common stock and will vest on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting that occurs at least 50 weeks after the prior year’s meeting. This is a stock-based compensation grant rather than an open-market purchase.
Nicaise Claude reported acquisition or exercise transactions in this Form 4 filing.
Sarepta Therapeutics director Claude Nicaise received a grant of 16,875 shares of common stock in the form of restricted stock units (RSUs). The RSUs were granted at no cash cost per share and increase his directly held position to 48,407 shares of common stock.
Each RSU represents the right to receive one share of Sarepta common stock. The RSUs will vest on the earlier of one year from the grant date or the next annual meeting of stockholders that occurs at least 50 weeks after the prior year’s annual meeting, aligning vesting with the company’s annual meeting cycle.
Chambers Michael Andrew reported acquisition or exercise transactions in this Form 4 filing.
Sarepta Therapeutics director Michael Andrew Chambers reported an equity award of 16,875 shares of common stock in the form of restricted stock units. The RSUs were granted at no cash cost per share and will vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, provided it occurs at least 50 weeks after the prior annual meeting. Following this grant, Chambers holds 27,535 shares directly, in addition to 476,492 shares held indirectly through a revocable trust.
Barry Richard reported acquisition or exercise transactions in this Form 4 filing.
Sarepta Therapeutics, Inc. reported that director Barry Richard received a grant of 16,875 shares of Common Stock as restricted stock units (RSUs) at a price of $0.00 per share. These RSUs will vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders that is at least 50 weeks after the prior year's annual meeting.
Following this grant, Richard directly holds 2,983,542 shares of Sarepta common stock. He also has indirect ownership of 10,000 shares through an LLC and 240,000 shares through a trust, as reported in the filing.
Sarepta Therapeutics, Inc. reported results from its annual stockholder meeting. Stockholders approved the new 2026 Equity Incentive Plan, which allows issuance of up to 6,286,841 shares of common stock under future awards, replacing the prior 2018 equity plan.
They also approved a new 2026 Employee Stock Purchase Plan, making 1,500,000 shares available for employee purchases and replacing the amended 2013 ESPP. All Class I director nominees were elected for two-year terms, executive compensation for 2025 received advisory approval, and KPMG LLP was ratified as independent auditor for the year ending December 31, 2026.
Sarepta Therapeutics, Inc. submitted a Form 13F holdings report signed by Ryan Wong on 05-13-2026. The report lists 1 Form 13F information table entry with a total reported value of $0 and shows 0 other included managers. The filing attests that the signatory is authorized and that the information is true and complete.